



DELIVER THE **POWER OF 3**

PreHevbrio is the Only 3-Antigen Hepatitis B Vaccine

Indication


PreHevbrio is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and older.

Select Important Safety Information

Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio.

Please see Important Safety Information on page 5.

Ordering & Reimbursement



HOW TO ACCESS PREHEVBRIO

PreHevbrio is covered by most insurance plans. For a list of Authorized Distributors, please email distribution at Distribution-US@vbivaccines.com or call 1-888-421-8808.

GETTING REIMBURSEMENT

TYPE	CODE	DESCRIPTION
CPT Drug Code	90759	Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use
CPT Administration Code	90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
HCPCS (Administration code for Medicare Part B)	G0010	Administration of hepatitis B vaccine
10-Digit NDC Number	75052-001-10	Package of 10 single-dose vials
11-Digit NDC Number	75052-0001-10	Package of 10 single-dose vials
MX Code	VBI	VBI Vaccines
CVX Code	220	Hepatitis B vaccine (recombinant)

Unit Dimensions: 1.77" x 4.53" x 1.69"

Select Important Safety Information

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of PreHevbrio.


Please see Important Safety Information on page 5.

Dosing & Administration

PreHevbrio
Hepatitis B Vaccine (Recombinant)

HOW TO USE PREHEVBRIO¹

PreHevbrio is administered at 0, 1, and 6 months as a series



3 DOSES
(1.0 mL each)

ADMINISTERED AT



m=months



PreHevbrio is an injectable suspension for intramuscular use, supplied in a **SINGLE-DOSE VIAL**

Supplied as a **PACKAGE OF 10** single-dose vials



ADMINISTER

by intramuscular injection. Shake the vial of PreHevbrio well to obtain a slightly opaque, white suspension.*

*Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.



STORE in refrigerator at 2-8° C (36-46° F). **Do not freeze**; discard if the vaccine has been frozen. Protect from light. Do not use the vaccine after the expiration date shown on the vial label.

Select Important Safety Information

Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio.

Please see Important Safety Information on page 5.

Adult Vaccination Against Hepatitis B (HBV) Has Changed

Effective April 2022, CDC's Advisory Committee on Immunization Practices (ACIP) adult HBV vaccination recommendations now include²:

19-59
years

Universal Recommendation

Adults aged 19-59 years should get vaccinated

60+
years

Adults aged 60+ with risk factors should get vaccinated, other adults aged 60+ may also get vaccinated

INDICATION

PreHevbrio is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. PreHevbrio is approved for use in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of PreHevbrio.

Immunocompromised persons, including those on immunosuppressant therapy, may have a diminished immune response to PreHevbrio.

PreHevbrio may not prevent hepatitis B infection, which has a long incubation period, in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common side effects (> 10%) in adults age 18-44, adults age 45-64, and adults age 65+ were pain and tenderness at the injection site, myalgia, fatigue, and headache.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women who received PreHevbrio during pregnancy. Women who receive PreHevbrio during pregnancy are encouraged to contact medinfo@vbivaccines.com or call 1-888-421-8808 (toll-free).

To report SUSPECTED ADVERSE REACTIONS, contact VBI Vaccines at 1-888-421-8808 (toll-free) or VAERS at 1-800-822-7967 or www.vaers.hhs.gov

Click [here](#) for Full Prescribing Information.

References

1. PREHEVBRIO Prescribing Information. Cambridge, MA. VBI Inc. **2.** Centers for Disease Control. Advisory Committee on Immunization Practices. <https://www.cdc.gov/vaccines/acip/index.html>. Accessed January 21, 2022.

PREHEVBRIO DELIVERS **THE POWER OF 3**

The Only 3-Antigen Hepatitis B Vaccine

For more information, visit www.prehevbrio.com



Please see Important Safety Information on page 5.

To report SUSPECTED ADVERSE REACTIONS, contact VBI Vaccines at 1-888-421-8808 (toll-free) or VAERS at 1-800-822-7967 or www.vaers.hhs.gov

 **PreHevbrio**
Hepatitis B Vaccine (Recombinant)

